Last data update: Nov 04, 2024. (Total: 48056 publications since 2009)
Records 1-9 (of 9 Records) |
Query Trace: Wilson WW[original query] |
---|
Sepsis program activities in acute care hospitals - National Healthcare Safety Network, United States, 2022
Dantes RB , Kaur H , Bouwkamp BA , Haass KA , Patel P , Dudeck MA , Srinivasan A , Magill SS , Wilson WW , Whitaker M , Gladden NM , McLaughlin ES , Horowitz JK , Posa PJ , Prescott HC . MMWR Morb Mortal Wkly Rep 2023 72 (34) 907-911 Sepsis, life-threatening organ dysfunction secondary to infection, contributes to at least 1.7 million adult hospitalizations and at least 350,000 deaths annually in the United States. Sepsis care is complex, requiring the coordination of multiple hospital departments and disciplines. Sepsis programs can coordinate these efforts to optimize patient outcomes. The 2022 National Healthcare Safety Network (NHSN) annual survey evaluated the prevalence and characteristics of sepsis programs in acute care hospitals. Among 5,221 hospitals, 3,787 (73%) reported having a committee that monitors and reviews sepsis care. Prevalence of these committees varied by hospital size, ranging from 53% among hospitals with 0-25 beds to 95% among hospitals with >500 beds. Fifty-five percent of all hospitals provided dedicated time (including assigned protected time or job description requirements) for leaders of these committees to manage a program and conduct daily activities, and 55% of committees reported involvement with antibiotic stewardship programs. These data highlight opportunities, particularly in smaller hospitals, to improve the care and outcomes of patients with sepsis in the United States by ensuring that all hospitals have sepsis programs with protected time for program leaders, engagement of medical specialists, and integration with antimicrobial stewardship programs. CDC's Hospital Sepsis Program Core Elements provides a guide to assist hospitals in developing and implementing effective sepsis programs that complement and facilitate the implementation of existing clinical guidelines and improve patient care. Future NHSN annual surveys will monitor uptake of these sepsis core elements. |
Intravenous antimicrobial starts among hemodialysis patients in the National Healthcare Safety Network Dialysis Component, 2016-2020
Wilson WW , Gouin KA , Fike L , Apata IW , Bell JM , Edwards JR , Novosad S , Kabbani S . Kidney360 2023 4 (7) 971-975 NHSN total IV antimicrobial start rates for patients on hemodialysis decreased from 2016-2020, | but rates unsupported by NHSN surveillance documentation did not. | 80% of reporting hemodialysis facilities had ≥1 unsupported IV antimicrobial start and the | fraction of facilities with unsupported starts increased yearly. | Accurate reporting and timely review of antimicrobial data is critical to understanding | prescribing trends and practices in hemodialysis facilities. |
Characteristics of Nursing Home Residents and Healthcare Personnel with Repeat Positive SARS-CoV-2 Tests ≥ 90 Days After Initial Infection: 4 U.S. Jurisdictions, July 2020 - March 2021.
Wilson WW , Hatfield KM , Tressler S , BickingKinsey C , Parra G , Zell R , Denson A , Williams C , Spicer KB , Kamal-Ahmed I , Abdalhamid B , Gemechu M , Folster J , Thornburg NJ , Tamin A , Harcourt JL , Queen K , Tong S , Jernigan JA , Crist M , Perkins KM , Reddy SC . Infect Control Hosp Epidemiol 2023 44 (5) 809-812 One in six nursing home residents and staff with positive SARS-CoV-2 tests 90 days after initial infection had specimen cycle thresholds (Ct) <30. Individuals with specimen Ct<30 were more likely to report symptoms but were not different from individuals with high Ct value specimens by other clinical and testing data. |
Outbreaks of SARS-CoV-2 infections in nursing homes during periods of Delta and Omicron predominance, United States, July 2021-March 2022
Wilson WW , Keaton AA , Ochoa LG , Hatfield KM , Gable P , Walblay KA , Teran RA , Shea M , Khan U , Stringer G , Ganesan M , Gilbert J , Colletti JG , Grogan EM , Calabrese C , Hennenfent A , Perlmutter R , Janiszewski KA , Brandeburg C , Kamal-Ahmed I , Strand K , Donahue M , Ashraf MS , Berns E , MacFarquhar J , Linder ML , Tran DJ , Kopp P , Walker RM , Ess R , Baggs J , Jernigan JA , Kallen A , Hunter JC . Emerg Infect Dis 2023 29 (4) 761-770 SARS-CoV-2 infections among vaccinated nursing home residents increased after the Omicron variant emerged. Data on booster dose effectiveness in this population are limited. During July 2021-March 2022, nursing home outbreaks in 11 US jurisdictions involving >3 infections within 14 days among residents who had received at least the primary COVID-19 vaccine(s) were monitored. Among 2,188 nursing homes, 1,247 outbreaks were reported in the periods of Delta (n = 356, 29%), mixed Delta/Omicron (n = 354, 28%), and Omicron (n = 536, 43%) predominance. During the Omicron-predominant period, the risk for infection within 14 days of an outbreak start was lower among boosted residents than among residents who had received the primary vaccine series alone (risk ratio [RR] 0.25, 95% CI 0.19-0.33). Once infected, boosted residents were at lower risk for all-cause hospitalization (RR 0.48, 95% CI 0.40-0.49) and death (RR 0.45, 95% CI 0.34-0.59) than primary vaccine-only residents. |
Transmission of Mycobacterium tuberculosis to healthcare personnel resulting from contaminated bone graft material, United States, June 2021- August 2022
Li R , Deutsch-Feldman M , Adams T , Law M , Biak C , Pitcher E , Drees M , Hernandez-Romieu AC , Filardo TD , Cropper T , Martinez A , Wilson WW , Althomsons SP , Morris SB , Wortham JM , Benowitz I , Schwartz NG , White K , Haddad MB , Glowicz JB . Clin Infect Dis 2023 76 (10) 1847-1849 A nationwide tuberculosis outbreak linked to a viable bone allograft product contaminated with Mycobacterium tuberculosis was identified in June 2021. Our subsequent investigation identified 73 healthcare personnel with new latent tuberculosis infection following exposure to the contaminated product, product recipients, surgical instruments, or medical waste. |
Multistate Outbreak of Melioidosis Associated with Imported Aromatherapy Spray.
Gee JE , Bower WA , Kunkel A , Petras J , Gettings J , Bye M , Firestone M , Elrod MG , Liu L , Blaney DD , Zaldivar A , Raybern C , Ahmed FS , Honza H , Stonecipher S , O'Sullivan BJ , Lynfield R , Hunter M , Brennan S , Pavlick J , Gabel J , Drenzek C , Geller R , Lee C , Ritter JM , Zaki SR , Gulvik CA , Wilson WW , Beshearse E , Currie BJ , Webb JR , Weiner ZP , Negrón ME , Hoffmaster AR . N Engl J Med 2022 386 (9) 861-868 Melioidosis, caused by the bacterium Burkholderia pseudomallei, is an uncommon infection that is typically associated with exposure to soil and water in tropical and subtropical environments. It is rarely diagnosed in the continental United States. Patients with melioidosis in the United States commonly report travel to regions where melioidosis is endemic. We report a cluster of four non-travel-associated cases of melioidosis in Georgia, Kansas, Minnesota, and Texas. These cases were caused by the same strain of B. pseudomallei that was linked to an aromatherapy spray product imported from a melioidosis-endemic area. |
Multisystem Inflammatory Syndrome in Adults After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Coronavirus Disease 2019 (COVID-19) Vaccination.
Belay ED , Godfred Cato S , Rao AK , Abrams J , Wilson WW , Lim S , Newton-Cheh C , Melgar M , DeCuir J , Webb B , Marquez P , Su JR , Meng L , Grome HN , Schlaudecker E , Talaat K , Edwards K , Barnett E , Campbell AP , Broder KR , Bamrah Morris S . Clin Infect Dis 2021 75 (1) e741-e748 BACKGROUND: Multisystem inflammatory syndrome in adults (MIS-A) was reported in association with the COVID-19 pandemic. MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines. METHODS: Reports of MIS-A patients received by the Centers for Disease Control and Prevention (CDC) after COVID-19 vaccines became available were assessed. Data collected on the patients included clinical and demographic characteristics and their vaccine status. The Vaccine Adverse Events Reporting System (VAERS) was also reviewed for possible cases of MIS-A. RESULTS: From December 14, 2020 to April 30, 2021, 20 patients who met the case definition for MIS-A were reported to CDC. Their median age was 35 years (range, 21-66 years), and 13 (65%) were male. Overall, 16 (80%) patients had a preceding COVID-19-like illness a median of 26 days (range 11-78 days) before MIS-A onset. All 20 patients had laboratory evidence of SARS-CoV-2 infection. Seven MIS-A patients (35%) received COVID-19 vaccine a median of 10 days (range, 6-45 days) before MIS-A onset; 3 patients received a second dose of COVID-19 vaccine 4, 17, and 22 days before MIS-A onset. Patients with MIS-A predominantly had gastrointestinal and cardiac manifestations and hypotension or shock. CONCLUSIONS: Although 7 patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection. Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring. |
Notes from the field: Tuberculosis outbreak linked to a contaminated bone graft product used in spinal surgery - Delaware, March-June 2021
Li R , Wilson WW , Schwartz NG , Hernandez-Romieu AC , Glowicz J , Hanlin E , Taylor M , Pelkey H , Briody CA , Gireesh L , Eskander M , Lingenfelter K , Althomsons SP , Stewart RJ , Free R , Annambhotla P , Basavaraju SV , Wortham JM , Morris SB , Benowitz I , Haddad MB , Hong R , Drees M . MMWR Morb Mortal Wkly Rep 2021 70 (36) 1261-1263 On May 25, 2021, a Delaware acute care hospital notified the Delaware Division of Public Health (DPH) of seven patients who developed tuberculosis after spinal surgery during March–April 2021. Hospital staff members identified a single common exposure: implantation of bone allograft material (product A) from a single product lot. DPH notified CDC, requested a field investigation, and issued a nationwide call for cases. In collaboration with the Food and Drug Administration, a CDC team was deployed to Delaware on June 2 to investigate the epidemiology of cases and opportunities for transmission and to provide prevention and treatment recommendations. On the same day, another state health department notified CDC about a person who developed tuberculosis after surgery involving the same product A lot, and the manufacturer issued a voluntary nationwide recall (1). |
Absence of SARS-CoV-2 infections among patients with end-stage renal disease following facility-wide testing in four outpatient hemodialysis facilities.
Wilson WW , Bardossy AC , Gable P , Herzig C , Beshearse E , Gualandi N , Sabour S , Brown N , Brown AC , Kutty P , Tobin-D'Angelo M , Lea JP , Apata IW , Novosad S , Hudson M , Hernandez-Romieu AC , Tobolowsky F , Lyons A , Gilbert S , Soda E , Biedron C , Korhonen L . Am J Infect Control 2021 49 (10) 1318-1321 Facility-wide testing performed at four outpatient hemodialysis facilities in the absence of an outbreak or escalating community incidence did not identify new SARS-CoV-2 infections and illustrated key logistical considerations essential to successful implementation of SARS-CoV-2 screening. Facilities could consider prioritizing facility-wide SARS-CoV-2 testing during suspicion of an outbreak in the facility or escalating community spread without robust infection control strategies in place. Being prepared to address operational considerations will enhance implementation of facility-wide testing in the outpatient dialysis setting. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Nov 04, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure